India 2009b.

Methods	Randomised, double‐blind, placebo‐controlled trial (2 arms of misoprostol and 1 arm of oxytocin).
Participants	300 women with healthy singleton pregnancies in spontaneous or induced labour at term were included. Exclusion criteria included known hypersensitivity/contraindication to prostaglandins, intrauterine fetal demise, antepartum haemorrhage, multiple pregnancy, malpresentation, cardiac disease, Rhesus‐negative mother, hypertensive disorders, and severe anaemia (haemoglobin < 7 g/dL).
Interventions	400 mcg sublingual misoprostol, 600 mcg sublingual misoprostol versus 5 IU IV oxytocin.
Outcomes	Blood loss during the 3rd and 4th stage of labour, duration of 3rd stage of labour, need for additional oxytocics, need for blood transfusion and adverse effects of the drugs.
Notes	Active management of third stage of labour 1 hour after delivery, the preweighted, blood‐soaked linen‐saver sheet and preweighted sanitary pads were weighted to assess maternal blood loss.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"computer‐generated random numbers."
Allocation concealment (selection bias)	Unclear risk	Unclear how the allocation concealment was done.
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow‐up or postrandomisation exclusions were reported.
Selective reporting (reporting bias)	Unclear risk	Not all of the primary outcomes of the review were reported.
Other bias	Low risk	Baseline demographic and clinical characteristics of patients were similar among the groups.